Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · Frontotemporal Dementia–Amyotrophic Lateral Sclerosis Spectrum

The Biology of the FTD-ALS Spectrum

At a Glance

The FTD-ALS spectrum is a shared disease process that can affect movement, speech, behavior, language, and judgment. TDP-43 changes and C9orf72 repeat expansions may be involved, while cognitive screening, multidisciplinary care, and caregiver support help guide decisions.

Receiving a diagnosis on the frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) spectrum is overwhelming. While these were once thought of as two separate diseases, doctors now understand them as two ends of the same biological spectrum [1][2]. This means that the brain and the motor system are being affected by the same underlying process.

In the FTD-ALS spectrum, the disease can start in different ways. Some people first notice muscle weakness or speech changes (ALS symptoms), while others first experience changes in personality, judgment, or language (FTD symptoms) [3][2]. Over time, many patients develop symptoms of both. Approximately 10% to 15% of people diagnosed with ALS will eventually meet the full clinical criteria for FTD, though up to 50% may experience milder cognitive or behavioral changes [4][5].

The Biology of the Spectrum

The link between these two conditions lies in the way certain proteins behave inside the body’s cells.

  • TDP-43 Proteinopathy: In most cases of FTD-ALS, a protein called TDP-43 stops working correctly [6]. Normally, this protein lives in the cell’s nucleus (the control center) and helps manage genetic instructions. In this disease, the protein “misfolds” and clumps together in the main body of the cell (cytoplasm) [6][7]. This causes a double problem: the nucleus loses the protein it needs to function, and the new clumps may become toxic to the cell [6][8]. Note that TDP-43 pathology is generally not confirmed by a routine test during life.
  • The C9orf72 Repeat Expansion: A frequent genetic cause of the FTD-ALS spectrum is a “repeat expansion” in the C9orf72 gene [9]. This expansion creates long, repetitive strands of genetic material that interfere with how cells clear out waste and transport materials [9][10]. While finding this expansion is a strong biological link, a negative genetic test does not rule out the disease, as there are other mechanisms [11][12].

Understanding Behavioral Changes

One of the hardest parts of this diagnosis for caregivers is seeing a loved one’s personality change. It is vital to remember: these changes are caused by physical damage to the brain, not a choice or a character flaw.

The FTD component often affects the frontal lobes, which control “executive functions” like empathy, impulse control, and social manners [13]. Common symptoms include:

  • Apathy: A profound loss of interest or initiative that can look like depression but is actually a loss of the brain’s “starter” mechanism [14].
  • Loss of Empathy: A person may seem cold or indifferent to the feelings of others because the brain regions that process social cues are deteriorating [15].
  • Dietary Changes: Many patients develop an intense craving for sweets or try to eat objects that aren’t food (hyperorality) [16][14].
  • Disinhibition: Acting impulsively or saying inappropriate things in social situations [17].

Navigating Care and Expectations

Because this condition is rare and complex, many local doctors may have limited experience managing the dual symptoms. Care is best handled at specialized, multidisciplinary centers where neurologists, speech therapists, and social workers work together to address both physical and cognitive needs [13][18].

In this spectrum, physical strength is not a reliable indicator of cognitive health. A patient may still be able to walk or speak clearly while having significant trouble making safe decisions or understanding complex instructions [19]. Conversely, someone with severe physical disability may have entirely preserved thinking and judgment. Formal screening using tools specifically designed for ALS, such as the ECAS (Edinburgh Cognitive and Behavioural ALS Screen), are useful to monitor cognitive health [13][19].

However, ECAS and MiND-B are screening tools, not legal capacity assessments. A low screening score does not automatically remove the person’s right to participate in decisions. Formal capacity assessment uses supported communication and clinical/legal evaluation, and capacity is specific to each individual decision.

Caregiver support is not a luxury; it is a clinical necessity. The combination of physical caregiving and managing difficult behavioral symptoms creates an immense burden that requires proactive support from social workers and specialized support groups [20][13].

Common questions in this guide

What is the FTD-ALS spectrum?
The FTD-ALS spectrum describes an overlap between frontotemporal dementia and amyotrophic lateral sclerosis. The same disease process can affect brain areas involved in behavior, language, and judgment as well as the motor system, so symptoms may include cognitive or behavioral changes along with muscle weakness or speech changes.
What does TDP-43 do in FTD-ALS?
TDP-43 is normally a protein inside a cell’s nucleus that helps manage genetic instructions. In many people with FTD-ALS, it misfolds and collects in the cell body, leaving the nucleus without enough of the protein and potentially harming the cell. This change is generally not confirmed by a routine test during life.
Why can FTD-ALS cause personality or eating changes?
These changes can occur when the disease affects frontal brain regions that help control initiative, empathy, impulse control, and social behavior. Apathy, loss of empathy, impulsive behavior, and strong cravings for sweets or non-food items are symptoms of brain disease, not a character flaw or deliberate choice.
Does a negative C9orf72 test rule out FTD-ALS?
No. A repeat expansion in C9orf72 is one frequent genetic cause, but FTD-ALS can result from other biological mechanisms. Genetic counseling can help explain what the test does and does not mean for family members.
How are thinking and behavior screened in someone with ALS?
Tools such as the ECAS and MiND-B are designed to screen cognitive and behavioral changes in people with ALS. They are screening tools, not legal capacity assessments; a low score alone does not remove a person’s right to participate in decisions. A formal capacity evaluation considers supported communication and the specific decision being made.
Should someone with FTD-ALS be seen at a specialized center?
A multidisciplinary center with experience in the FTD-ALS spectrum can coordinate neurology, speech therapy, social work, and other support for both physical and cognitive needs. This can be especially useful because physical strength does not reliably show how well someone can think or make safe decisions.
What support do caregivers need when FTD and ALS overlap?
Caregivers may face both physical caregiving tasks and difficult behavioral changes, which can create a major burden. Planned support from social workers, specialized support groups, and the medical team can help address safety, communication, daily care, and caregiver well-being.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my loved one been formally assessed using an ALS-specific screening tool like the ECAS or MiND-B to distinguish between ALS-FTD and milder cognitive changes?
  2. 2.Given the dual diagnosis, should we be seen at a multidisciplinary center that specializes in the FTD-ALS spectrum specifically?
  3. 3.What is the plan for reassessing decision-making capacity as the disease progresses, especially regarding feeding and breathing support?
  4. 4.Can you explain the specific behavioral symptoms we are seeing (like apathy or dietary changes) in the context of the brain regions being affected?
  5. 5.Is genetic testing for the C9orf72 expansion appropriate for our family, and what resources are available for genetic counseling?
  6. 6.How does this dual diagnosis change the expected timeline and management of physical symptoms compared to 'pure' ALS?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria.

    Strong MJ, Abrahams S, Goldstein LH, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2017; (18(3-4)):153-174 doi:10.1080/21678421.2016.1267768.

    PMID: 28054827
  2. 2

    Cognitive and Behavioral Manifestations in ALS: Beyond Motor System Involvement.

    Rusina R, Vandenberghe R, Bruffaerts R

    Diagnostics (Basel, Switzerland) 2021; (11(4)) doi:10.3390/diagnostics11040624.

    PMID: 33808458
  3. 3

    Frontotemporal Dementia.

    Olney NT, Spina S, Miller BL

    Neurologic clinics 2017; (35(2)):339-374 doi:10.1016/j.ncl.2017.01.008.

    PMID: 28410663
  4. 4

    Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study.

    Bersano E, Sarnelli MF, Solara V, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(5-6)):373-379 doi:10.1080/21678421.2020.1771732.

    PMID: 32484726
  5. 5

    Cognitive impairment across ALS clinical stages in a population-based cohort.

    Chiò A, Moglia C, Canosa A, et al.

    Neurology 2019; (93(10)):e984-e994 doi:10.1212/WNL.0000000000008063.

    PMID: 31409738
  6. 6

    Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.

    Melamed Z, López-Erauskin J, Baughn MW, et al.

    Nature neuroscience 2019; (22(2)):180-190 doi:10.1038/s41593-018-0293-z.

    PMID: 30643298
  7. 7

    Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

    Root J, Merino P, Nuckols A, et al.

    Neurobiology of disease 2021; (154()):105360 doi:10.1016/j.nbd.2021.105360.

    PMID: 33812000
  8. 8

    Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns.

    Pérez-Berlanga M, Wiersma VI, Zbinden A, et al.

    The EMBO journal 2023; (42(17)):e111719 doi:10.15252/embj.2022111719.

    PMID: 37431963
  9. 9

    Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons.

    Shi Y, Lin S, Staats KA, et al.

    Nature medicine 2018; (24(3)):313-325 doi:10.1038/nm.4490.

    PMID: 29400714
  10. 10

    Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes.

    Jiang X, Schaeffer L, Patni D, et al.

    Science (New York, N.Y.) 2026; (391(6785)):eadv2600 doi:10.1126/science.adv2600.

    PMID: 41643021
  11. 11

    G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons.

    Rothstein JD, Baskerville V, Rapuri S, et al.

    Acta neuropathologica 2023; (147(1)):1 doi:10.1007/s00401-023-02652-3.

    PMID: 38019311
  12. 12

    C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy.

    Cook CN, Wu Y, Odeh HM, et al.

    Science translational medicine 2020; (12(559)) doi:10.1126/scitranslmed.abb3774.

    PMID: 32878979
  13. 13

    Pan-Asian consortium for treatment and research in ALS (PACTALS) guidelines for management of amyotrophic lateral sclerosis.

    Vucic S, Shahrizaila N, Kano O, et al.

    The Lancet regional health. Western Pacific 2025; (62()):101684 doi:10.1016/j.lanwpc.2025.101684.

    PMID: 41018945
  14. 14

    Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis.

    Saxon JA, Thompson JC, Harris JM, et al.

    Journal of neurology, neurosurgery, and psychiatry 2020; (91(12)):1304-1311 doi:10.1136/jnnp-2020-323969.

    PMID: 33055142
  15. 15

    The frontotemporal dementia-motor neuron disease continuum.

    Burrell JR, Halliday GM, Kril JJ, et al.

    Lancet (London, England) 2016; (388(10047)):919-31.

    PMID: 26987909
  16. 16

    Clinical and imaging correlates of hyperorality in syndromes associated with frontotemporal lobar degeneration.

    Altomare D, Bracca V, Premi E, et al.

    Psychiatry and clinical neurosciences 2024; (78(12)):818-825 doi:10.1111/pcn.13751.

    PMID: 39375835
  17. 17

    Examining the language and behavioural profile in FTD and ALS-FTD.

    Saxon JA, Thompson JC, Jones M, et al.

    Journal of neurology, neurosurgery, and psychiatry 2017; (88(8)):675-680 doi:10.1136/jnnp-2017-315667.

    PMID: 28596248
  18. 18

    Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder.

    Zucchi E, Ticozzi N, Mandrioli J

    Frontiers in neuroscience 2019; (13()):175 doi:10.3389/fnins.2019.00175.

    PMID: 30914912
  19. 19

    Cognitive and behavioural impairment in amyotrophic lateral sclerosis.

    Pender N, Pinto-Grau M, Hardiman O

    Current opinion in neurology 2020; (33(5)):649-654 doi:10.1097/WCO.0000000000000862.

    PMID: 32833751
  20. 20

    Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease.

    Liu S, Liu J, Wang XD, et al.

    International psychogeriatrics 2018; (30(8)):1131-1138 doi:10.1017/S1041610217002630.

    PMID: 29223171

This page is for informational purposes only and does not constitute medical advice. A neurologist and multidisciplinary care team should interpret your loved one’s symptoms, screening results, and genetic testing.

Get notified when new evidence is published on Frontotemporal dementia with motor neuron disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.